A role for pharmacists in community-based post-discharge warfarin management: protocol for the 'the role of community pharmacy in post hospital management of patients initiated on warfarin' study.
BACKGROUND
Shorter periods of hospitalisation and increasing warfarin use have placed stress on community-based healthcare services to care for patients taking warfarin after hospital discharge, a high-risk period for these patients. A previous randomised controlled trial demonstrated that a post-discharge service of 4 home visits and point-of-care (POC) International Normalised Ratio (INR) testing by a trained pharmacist improved patients' outcomes. The current study aims to modify this previously trialled service model to implement and then evaluate a sustainable program to enable the smooth transition of patients taking warfarin from the hospital to community setting.


METHODS
The service will be trialled in 8 sites across 3 Australian states using a prospective, controlled cohort study design. Patients discharged from hospital taking warfarin will receive 2 or 3 home visits by a trained 'home medicines review (HMR)-accredited' pharmacist in their 8 to 10 days after hospital discharge. Visits will involve a HMR, comprehensive warfarin education, and POC INR monitoring in collaboration with patients' general practitioners (GPs) and community pharmacists. Patient outcomes will be compared to those in a control, or 'usual care', group. The primary outcome measure will be the proportion of patients experiencing a major bleeding event in the 90 days after discharge. Secondary outcome measures will include combined major bleeding and thromboembolic events, death, cessation of warfarin therapy, INR control at 8 days post-discharge and unplanned hospital readmissions from any cause. Stakeholder satisfaction will be assessed using structured postal questionnaire mailed to patients, GPs, community pharmacists and accredited pharmacists at the completion of their study involvement.


CONCLUSIONS
This study design incorporates several aspects of prior interventions that have been demonstrated to improve warfarin management, including POC INR testing, warfarin education and home visits by trained pharmacists. It faces several potential challenges, including the tight timeframe for patient follow-up in the post-discharge period. Its strengths lie in a strong multidisciplinary team and the utilisation of existing healthcare frameworks. It is hoped that this study will provide the evidence to support the national roll-out of the program as a new Australian professional community pharmacy service.


BACKGROUND
Australian New Zealand Clinical Trials Registry Number 12608000334303.
Unit for Medication Outcomes Research and Education, School of Pharmacy, University of Tasmania, Hobart, Tasmania, Australia. leanne.stafford@utas.edu.au
Leanne
L
Stafford
Gregory M
GM
Peterson
Luke R E
LR
Bereznicki
Shane L
SL
Jackson
D000925:Anticoagulants / Q000627:therapeutic use*; D001315:Australia; D015331:Cohort Studies; D003266:Continuity of Patient Care; D006801:Humans; D017063:Outcome Assessment, Health Care; D010351:Patient Discharge; D010595:Pharmacists; D024382:Professional Role; D011446:Prospective Studies; D011795:Surveys and Questionnaires; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin
Am J Med. 1991 Jun;90(6):667-74
2042681
Br J Haematol. 2001 Jun;113(4):847-52
11442473
Am J Hosp Pharm. 1992 Feb;49(2):387-94
1554003
Ann Pharmacother. 2003 Jun;37(6):799-803
12773064
Int J Qual Health Care. 2001 Jun;13(3):209-13
11476145
Clin Lab Haematol. 1988;10(1):109-12
3365930
Pharm World Sci. 2008 Dec;30(6):810-5
18551383
J Qual Clin Pract. 1999 Mar;19(1):7-12
10096717
Br J Haematol. 2003 Sep;122(5):825-8
12930396
Chest. 2005 Jun;127(6):2049-56
15947319
J Clin Pathol. 2007 Mar;60(3):311-4
16751303
JAMA. 1998 Apr 15;279(15):1200-5
9555760
Am J Med. 1998 Aug;105(2):91-9
9727814
Thromb Res. 2008;123(2):381-9
18585761
Pharmacotherapy. 2010 Apr;30(4):330-8
20334453
Ann Intern Med. 2000 Nov 7;133(9):687-95
11074901
Thromb Res. 2008;122(6):774-5
18045664
J Qual Clin Pract. 1999 Mar;19(1):55-9
10096727
Ann Pharmacother. 2006 Apr;40(4):633-8
16551766
J Am Geriatr Soc. 2002 Aug;50(8):1439-45; discussion 1446-7
12165003
Lancet. 1996 Aug 17;348(9025):423-8
8709780
Expert Rev Cardiovasc Ther. 2008 Jan;6(1):57-70
18095907
Cardiol Clin. 2008 May;26(2):157-67, v
18406992
J Intern Med. 2001 Oct;250(4):327-41
11576320
Am J Med. 1989 Aug;87(2):144-52
2787958
J Clin Pharm Ther. 2005 Aug;30(4):345-53
15985048
Circulation. 2007 May 29;115(21):2689-96
17515465
Aust Fam Physician. 2004 Jun;33(6):477-8
15253617
Am J Med. 1999 Nov;107(5):414-24
10569295
Thromb Res. 2009 Apr;123(6):909-13
19042011
Am J Med. 1993 Sep;95(3):315-28
8368229
Thromb Res. 2008;123 Suppl 1:S36-41
18804262
Health Qual Life Outcomes. 2004 May 06;2:22
15132746
Ann Intern Med. 1993 Apr 1;118(7):511-20
8280198
Ann Intern Med. 1999 Oct 5;131(7):537-8
10507965
Am Heart J. 2008 Jul;156(1):148-54
18585510
Health Qual Life Outcomes. 2007 Apr 27;5:21
17462100
Patient Educ Couns. 2006 Dec;64(1-3):50-60
16843634
Chest. 2006 May;129(5):1155-66
16685005
Arch Intern Med. 2000 Jan 10;160(1):41-6
10632303
J Qual Clin Pract. 1999 Mar;19(1):19-22
10096719
J Qual Clin Pract. 1999 Mar;19(1):61-2
10096728
Chest. 2008 Jun;133(6 Suppl):160S-198S
18574265
Age Ageing. 2002 Mar;31(2):141-3
11937478
Br J Haematol. 2007 Jan;136(1):26-9
17116128
Aust J Rural Health. 2004 Oct;12(5):197-200
15588262
J Intern Med. 2004 Aug;256(2):137-44
15257726
Chest. 2001 Jan;119(1 Suppl):108S-121S
11157645
J Thromb Haemost. 2005 May;3(5):955-61
15869591
Am J Med. 1986 Aug;81(2):255-9
3740082
J Thromb Haemost. 2005 Apr;3(4):692-4
15842354
Pharmacotherapy. 1999 Jun;19(6):787-93
10391426